Ligand Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Brent climbs $1 on uncertainty over end to Iran war
- Atlassian results seen as 'game changer' for AI kills software worries
- The Trade Desk hit by Wall St downgrades after disappointing Q2 results, outlook
- Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
- S&P closes at record high as soft jobs report eases rate-hike concerns
- US suffers unexpected job losses in July, markets dial back rate hike expectations
- Atlassian results seen as 'game changer' for AI kills software worries
- Microsoft only US hyperscaler with positive free cash flow as AI capex bites
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Deutsche Bank Downgrades Ligand Pharma (LGND) to Sell
August 5, 2016 6:45 AM EDTDeutsche Bank downgraded Ligand Pharma (NASDAQ: LGND) from Hold to Sell with a price target of $110.00 (from $104.00). The downgrade was tied to valuation.
Analyst Gregg Gilbert said, "Our model and $110 target factor in continued growth for key royalty drivers (particularly AMGNs Kyprolis and Novartis Promacta), growth in technology deals (tied to Captisol and other platforms), and launches of new... More
Ligand Pharma (LGND) Tops Q2 EPS by 10c; Affirms FY16 Outlook
August 4, 2016 8:56 AM EDTLigand Pharma (NASDAQ: LGND) reported Q2 EPS of $0.50, $0.10 better than the analyst estimate of $0.40. Revenue for the quarter came in at $19.5 million versus the consensus estimate of $18.12 million.
The Company affirms expectations for full-year 2016 total revenues to be between $115 million and $119... More
